absa data-first generative AI drug discovery company, partners with semiconductor company AMD to deploy AMD Instinct accelerator and ROCm software to power critical AI drug discovery workloads and Absci’s advanced De Novo antibody design models I’m doing it.
In addition, AMD has invested $20 million in Absci. This investment will be structured as a private investment in public equity.
The purpose of this strategic partnership is to create better biology for patients using AI solutions optimized for complex biological modeling that deliver superior performance, lower infrastructure costs, and faster innovation cycles. to support Absci’s mission to create pharmaceutical formulations faster.
“At Absci, we are always looking for ways to push the boundaries of what is possible in drug discovery,” Absci founder and CEO Sean McClain said in a statement.
“This partnership with AMD is a unique opportunity to work closely with a partner who is passionate about supporting our needs while providing the most efficient and innovative AI solutions available. It gives us an advantage.”
McClain added that AMD’s high-performance computers will allow the company to further develop the next generation of antibody therapeutics.
Mark Papermaster, AMD’s executive vice president and chief technology officer, said Absci is at the forefront of AI-driven drug discovery, further accelerating therapeutic breakthroughs and expanding biologic drug development. We are proud to partner with AMD to transform the way we develop.
“Absci’s groundbreaking work in AI drug discovery is a perfect fit for AMD’s high-performance computing solutions and software designed for the most demanding AI workloads,” Papermaster said in a statement.
bigger trends
In 2023, Absci announced a $247 million partnership with pharmaceutical giant AstraZeneca focused on accelerating the discovery of new cancer treatments with the help of genAI technology.
This project leveraged Absci’s integrated drug discovery platform. The platform combines scalable wet lab technology and AI to facilitate optimization of multiple drug properties that are critical to therapeutic benefit and knowledge of AstraZeneca’s oncology research and development. The goal of the collaboration was to leverage Absci’s De Novo “zero shot” AI model to deliver new and improved antibody therapies for cancer.
In the same year, Abshi Drug discovery partnership with Almirall, a global biopharmaceutical company focused on medical dermatology, to develop and commercialize AI-designed treatments to combat chronic and debilitating dermatological diseases. concluded.
This partnership marks a new step in AI drug discovery, combining Absci’s integrated drug discovery platform with Almirall’s dermatology expertise, with the goal of bringing life-changing medicines to patients.
abs Oncology bioinformatics company M2GEN also announced a partnership to develop and quickly bring new cancer treatments to market. Absci’s generative AI drug discovery platform leverages M2GEN’s clinical and molecular dataset, ORIEN AVATAR (AVATAR), to accelerate the development of therapeutics for a variety of malignancies and patient profiles in the fight against cancer. Bringing AI drug discovery to you.
